Duopharma Biotech Berhad (KLSE:DPHARMA)

Duopharma Biotech Berhad Cash Flow Statement

Financials in millions MYR. Fiscal year is January - December.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	102.21	87.46	62.65	52.65	70.11	65.68
Depreciation & Amortization	39.95	40.68	40.58	38.76	33.48	29.66
Other Amortization	4.83	4.83	4.81	4.29	2.72	2.29
Loss (Gain) From Sale of Assets	-	-0.01	-0.39	-	-	0.01
Asset Writedown & Restructuring Costs	9.52	9.52	0.02	2.43	-	0.1
Provision & Write-off of Bad Debts	0.32	-0.53	-1.43	4.1	-0.49	0.1
Other Operating Activities	21.46	21.07	11.44	-7.11	22.74	7.29
Change in Accounts Receivable	-39.12	-28.87	-46.6	-5.81	-13.28	-4.14
Change in Inventory	-57.49	-60.67	-15.35	-12.39	-53.36	-78.43
Change in Accounts Payable	1.2	33.36	27.62	-28.1	8.35	20.64
Operating Cash Flow	82.86	106.83	83.34	48.8	70.27	43.2
Operating Cash Flow Growth	-37.86%	28.18%	70.77%	-30.54%	62.63%	-39.45%

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Capital Expenditures	-18.34	-26.84	-23.57	-32.95	-65.18	-109.36
Sale of Property, Plant & Equipment	0.2	0.21	0.5	-	-	0.02
Sale (Purchase) of Intangibles	-5.82	-6.34	-10.32	-6.61	-5.84	-5.64
Investment in Securities	-	-	-	-6.42	-	-2.07
Other Investing Activities	5.97	5.87	5.97	2.75	1.52	1.2
Investing Cash Flow	-18	-27.1	-27.43	-43.23	-69.5	-115.86

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Long-Term Debt Issued	-	58.15	93.37	486.35	85.67	186.78
Long-Term Debt Repaid	-	-78.75	-128.87	-369.97	-59.27	-89.46
Net Debt Issued (Repaid)	-21.55	-20.6	-35.5	116.37	26.4	97.33
Common Dividends Paid	-43.77	-33.67	-26.93	-8.85	-8.2	-44.96
Financing Cash Flow	-65.32	-54.27	-62.43	107.52	18.2	52.37

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Foreign Exchange Rate Adjustments	0.94	0.87	0.56	-0.23	0.69	0.24
Net Cash Flow	0.49	26.33	-5.96	112.87	19.66	-20.05

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Free Cash Flow	64.52	79.99	59.77	15.86	5.08	-66.16
Free Cash Flow Growth	-35.01%	33.83%	276.91%	211.98%	-	-
Free Cash Flow Margin	6.94%	8.59%	7.35%	2.25%	0.73%	-10.35%
Free Cash Flow Per Share	0.07	0.08	0.06	0.02	0.01	-0.07
Levered Free Cash Flow	36.88	50.92	31.95	-10.33	-6.71	-60.93
Unlevered Free Cash Flow	51.31	66.02	48.05	0.72	-1.02	-56.91

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash Interest Paid	23.44	24.52	27.02	21.71	16.54	11.97
Cash Income Tax Paid	15.3	17.42	10.66	16.83	24.51	11.66
Change in Working Capital	-95.41	-56.19	-34.32	-46.3	-58.29	-61.93

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error